Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$81.24 USD

81.24
844,876

-2.22 (-2.66%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $81.24 0.00 (0.00%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for HAE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Haemonetics Corporation falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 284 260 192 137
Receivables NA 179 159 128 165
Notes Receivable NA 0 0 0 0
Inventories NA 259 293 323 270
Other Current Assets NA 47 44 51 31
Total Current Assets NA 770 756 694 604
Net Property & Equipment NA 311 258 218 253
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 5 4 6 4
Intangibles NA 742 778 832 344
Deposits & Other Assets NA 107 63 71 62
Total Assets NA 1,935 1,860 1,820 1,267
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 12 214 17 77
Accounts Payable NA 64 58 50 51
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 64 49 48 49
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 112 121 139 98
Total Current Liabilities NA 252 442 254 275
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 36 29 44 11
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 754 559 691 306
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 75 80 100 89
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,117 1,110 1,088 680
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 595 572 603 553
Retained Earnings NA 253 202 158 79
Other Equity NA -30 -26 -30 -45
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 818 749 732 587
Total Liabilities & Shareholder's Equity NA 1,935 1,860 1,820 1,267
Total Common Equity 0 818 749 732 587
Shares Outstanding 50.70 50.40 51.10 50.80 50.30
Book Value Per Share 0.00 16.23 14.67 14.40 11.67

Fiscal Year End for Haemonetics Corporation falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 194 351 286 284
Receivables NA 212 174 177 179
Notes Receivable NA 0 0 0 0
Inventories NA 304 286 289 259
Other Current Assets NA 55 55 50 47
Total Current Assets NA 765 866 802 770
Net Property & Equipment NA 319 308 304 311
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 5 5 5 5
Intangibles NA 984 716 734 742
Deposits & Other Assets NA 127 117 117 107
Total Assets NA 2,200 2,011 1,962 1,935
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 14 14 14 12
Accounts Payable NA 57 80 78 64
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 59 46 33 64
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 132 125 112 112
Total Current Liabilities NA 262 264 237 252
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 62 35 37 36
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 857 749 751 754
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 70 72 75
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,257 1,118 1,098 1,117
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 627 617 610 595
Retained Earnings NA 340 309 284 253
Other Equity NA -24 -33 -30 -30
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 943 894 865 818
Total Liabilities & Shareholder's Equity NA 2,200 2,011 1,962 1,935
Total Common Equity 0 943 894 865 818
Shares Outstanding 50.70 50.70 50.70 50.60 50.40
Book Value Per Share 0.00 18.61 17.63 17.09 16.23